Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Cherian, Beena
- Antidiabetic Activity of Bioactive Compounds in Pleurotus florida Using Protein Receptors
Abstract Views :78 |
PDF Views:1
Authors
Beena Cherian
1,
Shilpa Jose
2
Affiliations
1 Department of Food Science and Nutrition, Mar Athanasios College for Advanced Studies, (MACFAST) Tiruvalla - 689 101, Kerala, IN
2 St. Teresa’s College, Ernakulam - 682 011, Kerala, IN
1 Department of Food Science and Nutrition, Mar Athanasios College for Advanced Studies, (MACFAST) Tiruvalla - 689 101, Kerala, IN
2 St. Teresa’s College, Ernakulam - 682 011, Kerala, IN
Source
The Indian Journal of Nutrition and Dietetics, Vol 59, No 3 (2022), Pagination: 294-299Abstract
Diabetes Mellitus (DM) is a chronic metabolic disorder due to the defects of insulin secretion (type 1) and increased cellular resistance to insulin (type 2). Mushrooms were found to be effective for reducing diabetic complications and for decreasing the blood glucose levels. When compared to synthetic drugs, the bioactive compounds isolated from mushrooms seem to be less toxic and free of side effects. The ethanol extracts of <I>Pleurotus florida</I> mushroom was used for the extraction of bioactive compounds. The compounds PFEE-1 to PFEE -14 were screened for drug likeness and molecular properties. For structural molecular biology and computer -assisted drug design, molecular docking is found to be a strong tool. It has been used in an attempt to identify and to expound the mechanism of action of the bioactive compounds in <I>Pleurotus florida</I> with the inhibition of GPCR40, PTPBI, PPAR and DPP4 protein receptor for controlling the blood sugar level. 14 bioactive compounds screened from Pleurotus florida mushroom ethanol extract was docked with the glide software based on the drug-likeness score. Ergosterol was found to be a potent inhibitor of DPP4, GPCR40, PPAR and PTPBI when compared to other bioactive compounds.Keywords
Molecular Docking, Pleurotus florida, Bioactive Compounds, GPCR40, PTPBI, PPAR and DPP4 Protein Receptor
References
- Harding, J.L., Pavkov, M.E., Magliano, D.J., Shaw, J.E. and Gregg, E.W. Global trends in diabetes complications: A review of current evidence. Diabetol., 2019, 62, 3-16. https://doi.org/10.1007/s00125-018-4711-2
- Reis F.S., Martins A., Vasconcelos M.H., Morales P. and Ferreira I.C. Functional foods based on extracts or compounds derived from Mushrooms. Trends Fd. Sci. Technol., 2017, 66, 48-62. doi: 10.1016/j.tifs.2017.05.010.
- De Silva, D., Rapior, S., Hyde, K. and Bahkali, A. Medicinal mushrooms in prevention and control of diabetes mellitus. Fungal Diversity, 2012, 56, 1-29. https://doi.org/10.1007/s13225-012-0187-4
- Teng, B.S., Wang, C.D., Zhang, D., Wu, J.S., Pan, D., Pan, L.F., Yang, H.J. and Zhou, P. Hypoglycemic effect and mechanism of a proteoglycan from ganodermalucidum on streptozotocin-induced type 2 diabetic rats. Eur. Rev. Med. Pharmacolog. Sci., 2012, 16, 166-175.
- Cui, B., Han, L., Qu, J. and Lv, Y. Hypoglycemic activity of Grifola frondosa rich in vanadium. Biolog. Trace Elem. Res., 2009, 131, 186-191. https://doi.org/10.1007/s12011-009-8355-4
- Konno, S., Aynehchi, S., Dolin, D., Schwartz, A., Choudhury, M. and Tazaki, H. Anticancer and hypoglycemic effects of polysaccharides in edible and medicinal maitake mushroom [Grifola frondosa (Dicks.:Fr.) S.F. Gray]. Int. J. Med. Mushrooms, 2002, 4, 131-142.
- Rahi, D. and Malik, D. Diversity of mushrooms and their metabolites of nutraceutical and therapeutic significance. J. Mycol., 2016, 2016, 1-18. https://doi.org/10.1155/2016/7654123
- Ho, L., Asyikeen Zulkifli, N. and Tan, T. An introduction to mushroom - edible mushroom: nutritional properties, potential nutraceutical values and Its Utilisation in Food Product Development. 2020. https://doi.org/10.5772/intechopen.91827
- Khan, M. and Tania, M. Nutritional and medicinal importance of Pleurotus mushrooms: An overview. Fd. Rev. Int., 2012, 28, 313-329. https://doi.org/10.1080/87559129.2011.637267
- McConkey, B.J., Sobolev, V. and Edelman, M. The performance of current methods in ligand-protein docking. Curr. Sci., 2002, 83, 845-856. http://www.jstor.org/stable/24107087
- Demuth, H.U., McIntosh, C.H. and Pederson, R.A. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochimica et Biophysica Acta, 2005, 1751, 33-44. https://doi.org/10.1016/j.bbapap.2005.05.010
- Behme, M.T., Dupré, J. and McDonald, T.J. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocrine Disorders, 2003, 3, 3. https://doi.org/10.1186/1472-6823-3-3
- Dupre, J., Behme, M.T., Hramiak, I.M., McFarlane, P., Williamson, M.P., Zabel, P. and McDonald, T.J. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes, 1995, 44, 626-630. https://doi.org/10.2337/diab.44.6.626.